


## COMPLIANCE REPORT ON CORPORATE GOVERNANCE

1. Name of Listed Entity: **Rainbow Children's Medicare Limited**
2. Quarter ending: **March 31, 2023**

| I. Composition of Board of Directors |                      |                |   |                             |                         |                   |                     |               |  |   |  |  |
|--------------------------------------|----------------------|----------------|---|-----------------------------|-------------------------|-------------------|---------------------|---------------|--|---|--|--|
| Title (Mr/ Ms)                       | Name of the Director | DIN            | Category (Chairperson/ Executive/ Non- Executive/ independent/ Nominee) | Initial date of Appointment | Date of Re- appointment | Date of Cessation | Tenure (In Months)* | Date of Birth | No. of Directorship in listed entities including this listed entity<br><br>[in Reference to Regulation 17A(1)] | No of Independent Directorship in listed entities Including this listed entity<br><br>[in reference to Regulation 17A(1)] | Number of Memberships in Audit/ Stakeholder Committee(s) including this listed entity<br><br>[Refer Regulation 26(1) of Listing Regulations] | No. of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity<br><br>[Refer Regulation 26(1) of Listing Regulations] |
| Mr.                                  | Ramesh Kancharla     | DIN - 00212270 | Executive Director, Chairperson & Managing Director                     | 07-08-1998                  | 11-08-2021              | -                 | -                   | 23-06-1961    | 1  | 0   | 2  | 0  |
| Mr.                                  | Ch Dinesh Kumar      | DIN – 01395841 | Executive Director  | 14-12-2005                  | 11-08-2021              | -                 | -                   | 19-12-1969    | 1  | 0   | 0  | 0  |
| Mr.                                  | Anil Dhawan          | DIN- 08191702  | Independent Director  | 30-08-2018                  | 30-08-2018              | -                 | 55.02               | 07-11-1961    | 1  | 1   | 2  | 0  |
| Mr.                                  | Aluri Srinivasa Rao  | DIN – 00147058 | Independent Director  | 15-03-2019                  | 15-03-2019              | -                 | 48.17               | 13-02-1965    | 1  | 1   | 2  | 0  |



|     |                       |                   |                         |            |            |   |       |            |   |   |   |   |
|-----|-----------------------|-------------------|-------------------------|------------|------------|---|-------|------------|---|---|---|---|
| Ms. | Sundari R<br>Pisupati | DIN –<br>01908852 | Independent<br>Director | 16-09-2021 | 16-09-2021 | - | 18.15 | 06-05-1971 | 1 | 1 | 4 | 1 |
| Mr. | Santanu<br>Mukherjee  | DIN –<br>07716452 | Independent<br>Director | 22-10-2021 | 22-10-2021 | - | 17.10 | 29-12-1956 | 5 | 5 | 6 | 3 |


Whether Regular chairperson appointed: **YES**

Whether Chairperson is related to Managing Director or CEO: **YES**

\* Tenure of Independent Directors has been counted from his/her initial date of appointment till March 31, 2023

## II. Composition of Committees

| Name of Committee                      | Whether Regular chairperson appointed | Name of Committee Members  | Category<br>(Chairperson/Executive/Non-Executive/Independent/Nominee) | Date of Appointment# | Date of Cessation |
|--|---------------------------------------|----------------------------|---|----------------------|-------------------|
| 1. Audit Committee                     | Yes                                   | 1. Mr. Santanu Mukherjee   | Chairperson - Independent Director                                    | 22-10-2021           | -                 |
|  |                                       | 2. Prof. Anil Dhawan       | Member - Independent Director   | 22-10-2021           | -                 |
|  |                                       | 3. Mr. Aluri Srinivasa Rao | Member - Independent Director   | 22-10-2021           | -                 |
|  |                                       | 4. Ms. Sundari R Pisupati  | Member - Independent Director   | 22-10-2021           | -                 |
| 2. Nomination & Remuneration Committee | Yes                                   | 1. Mr. Aluri Srinivasa Rao | Chairperson - Independent Director                                    | 12-12-2019           | -                 |
|  |                                       | 2. Prof. Anil Dhawan       | Member - Independent Director   | 16-11-2018           | -                 |
|  |                                       | 3. Ms. Sundari R Pisupati  | Member - Independent Director   | 16-09-2021           | -                 |
|  |                                       | 4. Mr. Santanu Mukherjee   | Member - Independent Director   | 22-10-2021           | -                 |
| 3. Risk Management Committee           | Yes                                   | 1. Mr. Santanu Mukherjee   | Chairperson - Independent Director                                    | 22-10-2021           | -                 |
|  |                                       | 2. Dr. Ramesh Kancharla    | Member - Executive Director,<br>Managing Director                     | 02-03-2016           | -                 |
|  |                                       | 3. Mr. Aluri Srinivasa Rao | Member - Independent Director   | 12-12-2019           | -                 |
|  |                                       | 4. Mr. R Gowrisankar       | Member – Chief Financial Officer                                      | 22-10-2021           | -                 |
|  |                                       | 5. Mr. Mahesh Madduri      | Member – Head of Strategy   | 22-10-2021           | -                 |






|  |     |                            |   |            |   |
|--|-----|----------------------------|---|------------|---|
| 4. Stakeholders Relationship Committee   | Yes | 1. Ms. Sundari R Pisupati  | Chairperson - Independent Director                | 22-10-2021 | - |
|  |     | 2. Dr. Ramesh Kancharla    | Member - Executive Director,<br>Managing Director | 22-10-2021 |   |
|  |     | 3. Prof. Anil Dhawan       | Member - Independent Director                     | 22-10-2021 | - |
|  |     | 4. Mr. Aluri Srinivasa Rao | Member - Independent Director                     | 22-10-2021 | - |
| 5. Corporate Social Responsibility   | Yes | 1. Prof. Anil Dhawan       | Chairperson - Independent Director                | 16-11-2018 | - |
|  |     | 2. Dr. Ramesh Kancharla    | Member - Executive Director,<br>Managing Director | 19-03-2014 |   |
|  |     | 3. Dr. Ch Dinesh Kumar     | Member - Executive Director                       | 22-10-2021 | - |
|  |     | 4. Ms. Sundari R Pisupati  | Member - Independent Director                     | 22-10-2021 | - |
|  |     | 5. Mr. Santanu Mukherjee   | Member - Independent Director                     | 22-10-2021 | - |
| # Date of appointment is mentioned as initial date of appointment of Directors in respective committees. |     |                            |   |            |   |

### III. Meeting of Board of Directors

| Date(s) of Meeting (if any) in the previous quarter | Date(s) of Meeting (if any) in the relevant quarter | Whether requirement of Quorum met | Total Number of Directors as on date of the Meeting | Number of Directors present | Number of independent directors present | Maximum gap between any two consecutive (in number of days) |
|---|---|-----------------------------------|---|-----------------------------|---|---|
| November 3, 2022                                    | February 9, 2023                                    | Yes                               | 6   | 6                           | 4                                       | 97 Days   |
|   | March 18, 2023                                      | Yes                               | 6   | 6                           | 4                                       | 36 Days   |

### IV. Meetings of Committees

| Date(s) of meeting of the committee in the relevant quarter | Whether requirement of Quorum met | Total Number of Directors as on date of the Meeting | Number of Directors present | Number of Independent Directors present | Number of Members attending the meeting (other than Board of Directors) | Date(s) of meeting of the committee in the previous quarter | Maximum gap between any two consecutive meetings in number of days |
|---|-----------------------------------|---|-----------------------------|---|---|---|--|
| <b>Audit Committee</b>                                      |                                   |   |                             |   |   |   |  |
| February 8, 2023  | Yes                               | 4   | 4                           | 4                                       | 0   | November 3, 2022  | 96 Days  |



| <b>Nomination and Remuneration Committee</b>                    |     |   |   |   |   |                  |         |
|---|-----|---|---|---|---|------------------|---------|
| February 8, 2023  | Yes | 4 | 4 | 4 | 0 | -                | -       |
| March 18, 2023  | Yes | 4 | 4 | 4 | 0 |                  | 37 Days |
| <b>Risk Management Committee</b>                                |     |   |   |   |   |                  |         |
| February 8, 2023  | Yes | 3 | 3 | 2 | 2 | November 3, 2022 | 96 Days |
| March 18, 2023  | Yes | 3 | 3 | 2 | 2 |                  | 37 Days |
| <b>Stakeholders Relationship Committee</b>                      |     |   |   |   |   |                  |         |
| No Meeting was held during the quarter                          |     |   |   |   |   |                  |         |
| <b>Corporate Social Responsibility Committee</b>                |     |   |   |   |   |                  |         |
| No Meeting was held during the quarter and the previous quarter |     |   |   |   |   |                  |         |

| <b>V. Related Party Transactions</b>   |                               |
|--|-------------------------------|
| Subject  | Compliance status (Yes/No/NA) |
| Whether prior approval of audit committee obtained   | Yes                           |
| Whether shareholder approval obtained for material RPT   | N.A                           |
| Whether details of RPT entered into pursuant to omnibus approval have been reviewed by the Audit Committee | Yes                           |

#### VI. Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:
  - a. Audit Committee
  - b. Nomination and Remuneration Committee
  - c. Stakeholders Relationship Committee
  - d. Risk Management Committee



3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. ~~This report and~~ or The report submitted in the previous quarter has been placed before Board of Directors.

For **Rainbow Children's Medicare Limited**



**Ashish Kapil**

**Company Secretary and Compliance Officer**




**Date:** April 20, 2023

**Place:** Hyderabad




**Format to be submitted by listed entity at the end of the financial year (for the whole of financial year)**

| <b>I. Disclosure on website in terms of Listing Regulations</b>            |  |   |
|--|--|---|
| <b>Item</b>  | <b>Compliance status<br/>(Yes/No/NA)</b> | <b>If yes provide link to Website. If No/ NA provide reasons</b>  |
| <b>As per regulation 46(2) of the LODR:</b>                                |  |   |
| a) Details of business   | Yes                                      | <a href="https://www.rainbowhospitals.in/about-us/who-we-are">https://www.rainbowhospitals.in/about-us/who-we-are</a>   |
| b) Terms and conditions of appointment of independent directors            | Yes                                      | <a href="https://www.rainbowhospitals.in/investor-relations/reports/policy/Terms%20and%20Conditions%20of%20appointment%20of%20Independent%20Directors.pdf">https://www.rainbowhospitals.in/investor-relations/reports/policy/Terms%20and%20Conditions%20of%20appointment%20of%20Independent%20Directors.pdf</a> |
| c) Composition of various committees of board of directors                 | Yes                                      | <a href="https://www.rainbowhospitals.in/investors-relations/board-&amp;-board-committees">https://www.rainbowhospitals.in/investors-relations/board-&amp;-board-committees</a>   |
| d) Code of conduct of board of directors and senior management personnel   | Yes                                      | <a href="https://www.rainbowhospitals.in/investor-relations/reports/policy/Code%20of%20conduct%20for%20Directors%20and%20Senior%20Management.pdf">https://www.rainbowhospitals.in/investor-relations/reports/policy/Code%20of%20conduct%20for%20Directors%20and%20Senior%20Management.pdf</a>                   |
| e) Details of establishment of vigil mechanism/ Whistle Blower policy      | Yes                                      | <a href="https://www.rainbowhospitals.in/investor-relations/reports/policy/Whistle_Blower_Policy.pdf">https://www.rainbowhospitals.in/investor-relations/reports/policy/Whistle_Blower_Policy.pdf</a>   |
| f) Criteria of making payments to non-executive directors                  | Yes                                      | <a href="https://www.rainbowhospitals.in/investor-relations/reports/policy/Nomination_and_Remuneration_Policy.pdf">https://www.rainbowhospitals.in/investor-relations/reports/policy/Nomination_and_Remuneration_Policy.pdf</a>   |
| g) Policy on dealing with related party transactions                       | Yes                                      | <a href="https://www.rainbowhospitals.in/investor-relations/reports/policy/Policy%20on%20dealing%20with%20Related%20Party%20Transactions.pdf">https://www.rainbowhospitals.in/investor-relations/reports/policy/Policy%20on%20dealing%20with%20Related%20Party%20Transactions.pdf</a>                           |
| h) Policy for determining 'material' subsidiaries                          | Yes                                      | <a href="https://www.rainbowhospitals.in/investor-relations/reports/policy/Policy%20for%20determining%20Material%20Subsidiary.pdf">https://www.rainbowhospitals.in/investor-relations/reports/policy/Policy%20for%20determining%20Material%20Subsidiary.pdf</a>   |
| i) Details of familiarization programmes imparted to independent directors | Yes                                      | <a href="https://www.rainbowhospitals.in/investors-relations/policies-&amp;-programs">https://www.rainbowhospitals.in/investors-relations/policies-&amp;-programs</a>   |
| j) Email address for grievance redressal and other relevant details        | Yes                                      | <a href="https://www.rainbowhospitals.in/investors-relations/investor-contact">https://www.rainbowhospitals.in/investors-relations/investor-contact</a>   |



|   |     |   |
|---|-----|---|
| k) Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances  | Yes | <a href="https://www.rainbowhospitals.in/investors-relations/investor-contact">https://www.rainbowhospitals.in/investors-relations/investor-contact</a>   |
| l) Financial results  | Yes | <a href="https://www.rainbowhospitals.in/investors-relations/quarterly-results">https://www.rainbowhospitals.in/investors-relations/quarterly-results</a>   |
| m) Shareholding pattern   | Yes | <a href="https://www.rainbowhospitals.in/investors-relations/stock-exchange-disclosures/shareholding-pattern">https://www.rainbowhospitals.in/investors-relations/stock-exchange-disclosures/shareholding-pattern</a>   |
| n) Details of agreements entered into with the media companies and/or their associates  | NA  | The Company hasn't entered into any agreements with the media companies or their associates, etc.   |
| o) Schedule of analyst or institutional investor meet and presentations made by the listed entity to analysts or institutional investors simultaneously with submission to stock exchange | Yes | <a href="https://www.rainbowhospitals.in/investors-relations/stock-exchange-disclosures/schedule-of-analyst-&amp;-institutional-investor-meeting">https://www.rainbowhospitals.in/investors-relations/stock-exchange-disclosures/schedule-of-analyst-&amp;-institutional-investor-meeting</a> |
| p) New name and the old name of the listed entity   | NA  | Not Applicable  |
| q) Advertisements as per Regulation 47 (1)  | Yes | <a href="https://www.rainbowhospitals.in/investors-relations/shareholder-information/newspaper-advertisement">https://www.rainbowhospitals.in/investors-relations/shareholder-information/newspaper-advertisement</a>   |
| r) Credit rating or revision in credit rating obtained by the entity for all its outstanding instruments  | NA  | <a href="https://www.rainbowhospitals.in/investors-relations/shareholder-information/credit-ratings">https://www.rainbowhospitals.in/investors-relations/shareholder-information/credit-ratings</a>   |
| s) Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year  | Yes | <a href="https://www.rainbowhospitals.in/investors-relations/subsidiary-financials">https://www.rainbowhospitals.in/investors-relations/subsidiary-financials</a>   |
| <b>As per other regulations of the LODR:</b>  |     |   |
| a) Whether company has provided information under separate section on its website as per Regulation 46(2)   | Yes | <a href="https://www.rainbowhospitals.in/investors-relations">https://www.rainbowhospitals.in/investors-relations</a>   |





|  |     |   |
|--|-----|---|
| b) Materiality Policy as per Regulation 30   | Yes | <a href="https://www.rainbowhospitals.in/investor-relations/reports/policy/Policy_on_determination_of_materiality_for_disclosure_of_events_or_information.pdf">https://www.rainbowhospitals.in/investor-relations/reports/policy/Policy_on_determination_of_materiality_for_disclosure_of_events_or_information.pdf</a> |
| c) Dividend Distribution policy as per Regulation 43A (as applicable)                | Yes | <a href="https://www.rainbowhospitals.in/investor-relations/reports/Dividend_Distribution_Policy.pdf">https://www.rainbowhospitals.in/investor-relations/reports/Dividend_Distribution_Policy.pdf</a>   |
| It is certified that these contents on the website of the listed entity are correct. |     |   |

| <b>II. Annual Affirmations</b> |   |                          |  |
|--------------------------------|---|--------------------------|--|
| <b>S. No</b>                   | <b>Particulars</b>  | <b>Regulation Number</b> | <b>Compliance Status (Yes/ No/ NA)</b> |
| 1.                             | Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility' | 16(1)(b) & 25(6)         | Yes                                    |
| 2.                             | Board composition   | 17(1), 17(1A) & 17(1B)   | Yes                                    |
| 3.                             | Meeting of Board of directors   | 17(2)                    | Yes                                    |
| 4.                             | Quorum of board meeting   | 17(2A)                   | Yes                                    |
| 5.                             | Review of Compliance Reports  | 17(3)                    | Yes                                    |
| 6.                             | Plans for orderly succession for appointments   | 17(4)                    | Yes                                    |
| 7.                             | Code of Conduct   | 17(5)                    | Yes                                    |
| 8.                             | Fees/ Compensation  | 17(6)                    | Yes                                    |
| 9.                             | Minimum Information   | 17(7)                    | Yes                                    |
| 10.                            | Compliance Certificate  | 17(8)                    | Yes                                    |
| 11.                            | Risk Assessment & Management  | 17(9)                    | Yes                                    |
| 12.                            | Performance Evaluation of Independent Directors   | 17(10)                   | Yes                                    |
| 13.                            | Recommendation of Board   | 17(11)                   | Yes                                    |
| 14.                            | Maximum number of directorship  | 17A                      | Yes                                    |
| 15.                            | Composition of Audit Committee  | 18(1)                    | Yes                                    |
| 16.                            | Meeting of Audit Committee  | 18(2)                    | Yes                                    |
| 17.                            | Composition of Nomination & Remuneration Committee  | 19(1) & (2)              | Yes                                    |
| 18.                            | Quorum of Nomination and Remuneration Committee meeting   | 19(2A)                   | Yes                                    |






|     |   |                             |     |
|-----|---|-----------------------------|-----|
| 19. | Meeting of Nomination & Remuneration Committee  | 19(3A)                      | Yes |
| 20. | Composition of Stakeholder Relationship Committee   | 20(1), 20(2) and 20(2A)     | Yes |
| 21. | Meeting of Stakeholder Relationship Committee   | 20(3A)                      | Yes |
| 22. | Composition and role of risk management committee   | 21(1),(2),(3),(4)           | Yes |
| 23. | Meeting of Risk Management Committee  | 21 (3A)                     | Yes |
| 24. | Vigil Mechanism   | 22                          | Yes |
| 25. | Policy for related party Transaction  | 23(1),(1A),(5),(6) (7)& (8) | Yes |
| 26. | Prior or Omnibus approval of Audit Committee for all related party transactions                                   | 23(2) & (3)                 | Yes |
| 27. | Approval for material related party transactions  | 23(4)                       | NA  |
| 28. | Disclosure of related party transactions on consolidated basis  | 23(9)                       | Yes |
| 29. | Composition of Board of Directors of unlisted material Subsidiary*  | 24(1)                       | NA  |
| 30. | Other Corporate Governance requirements with respect to subsidiary of listed entity**                             | 24(2),(3),(4),(5) & (6)     | Yes |
| 31. | Annual Secretarial Compliance Report***   | 24A                         | Yes |
| 32. | Alternate Director to Independent Director  | 25(1)                       | NA  |
| 33. | Maximum Tenure  | 25 (2)                      | Yes |
| 34. | Meeting of independent directors  | 25(3) & (4)                 | Yes |
| 35. | Familiarization of independent directors  | 25(7)                       | Yes |
| 36. | Declaration from Independent Director   | 25(8) & (9)                 | Yes |
| 37. | Directors and Officers insurance  | 25(10)                      | Yes |
| 38. | Memberships in Committees   | 26(1)                       | Yes |
| 39. | Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel | 26(3)                       | Yes |
| 40. | Disclosure of Shareholding by Non-Executive Directors   | 26(4)                       | NA  |
| 41. | Policy with respect to Obligations of directors and senior management   | 26(2) & 26(5)               | Yes |

**Any other information to be provided**

\* The Company does not have any material subsidiary Company.

\*\* Regulations 24(5) & (6) are not applicable to the Company

\*\*\*As the Company got listed w.e.f. May 10, 2022, the annual secretarial compliance report was not applicable for the previous year ended March 31, 2022. Further, for the financial year ended on March 31, 2023, Company will submit the said report within stipulated timelines.



**III. Affirmation:**

| Particulars   | Compliance Status (Yes/No/NA) |
|---|-------------------------------|
| The Company has approved a Material Subsidiary Policy and the Corporate Governance requirements with respect to the subsidiaries of the Company have been complied. | Yes                           |

For Rainbow Children's Medicare Limited



**Ashish Kapil**  
Company Secretary and Compliance Officer



**Date:** April 20, 2023

**Place:** Hyderabad

**Additional Information to be submitted twice a year, on a half yearly basis by the listed entity at the end of every 6 months of the Financial Year/  
Half Year ending – March 31, 2023**

**I. Disclosure of Loans/ guarantees/ comfort letters / securities etc.** refer note below

**(A) Any loan or any other form of debt advanced by the listed entity directly or indirectly to:**

| Entity   | Aggregate amount advanced during six months | Balance outstanding at the end of six months |
|--|---|--|
| Promoter or any other entity controlled by them                        | NIL   | NIL  |
| Promoter Group or any other entity controlled by them                  | NIL   | NIL  |
| Directors (including relatives) or any other entity controlled by them | NIL   | NIL  |
| KMPs or any other entity controlled by them                            | NIL   | NIL  |

**(B) Any guarantee/ comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:**

| Entity   | Type (guarantee, comfort letter etc.) | Aggregate amount of Issuance during six months | Balance outstanding at the end of six months (taking into account any invocation) |
|--|---------------------------------------|--|---|
| Promoter or any other entity controlled by them                        | NIL                                   | NIL  | NIL   |
| Promoter Group or any other entity controlled by them                  | NIL                                   | NIL  | NIL   |
| Directors (including relatives) or any other entity controlled by them | NIL                                   | NIL  | NIL   |
| KMPs or any other entity controlled by them                            | NIL                                   | NIL  | NIL   |



*Debanjan*  
20/04/2023



(C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

| Entity   | Type of security<br>(cash, shares etc.) | Aggregate value of<br>security provided<br>during six months | Balance outstanding at the end<br>of six months |
|--|---|--|---|
| Promoter or any other entity controlled by them                        | NIL                                     | NIL  | NIL   |
| Promoter Group or any other entity controlled by them                  | NIL                                     | NIL  | NIL   |
| Directors (including relatives) or any other entity controlled by them | NIL                                     | NIL  | NIL   |
| KMPs or any other entity controlled by them                            | NIL                                     | NIL  | NIL   |

**II. Affirmations:**

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.

For Rainbow Children's Medicare Limited

*R Gowsankar*  
20/04/2023  
**R Gowsankar**  
Chief Financial Officer



Date: April 20, 2023

Place: Hyderabad

**Note:**

- These disclosures shall exclude any loan (or other form of debt), guarantee / comfort letter (by whatever name called) or security provided in connection with any loan or any other form of debt;
  - by a government company to/ for the Government or government company
  - by the listed entity to/for its subsidiary [and joint-venture company] whose accounts are consolidated with the listed entity.
  - by a banking company or an insurance company; and
  - by the listed entity to its employees or directors as a part of the service conditions
- If the Listed Entity would like to provide any other information, the same may be indicated as Para D in the above table.